Valdecoxib

Last updated
Valdecoxib
Valdecoxib2DACS.svg
Clinical data
Trade names Bextra
Pregnancy
category
Routes of
administration 		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 83%
Protein binding 98%
Metabolism Hepatic (CYP3A4 and 2C9 involved)
Elimination half-life 8 to 11 hours
Excretion Renal
Identifiers
  • 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.229.918 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H14N2O3S
Molar mass 314.36 g·mol−1
3D model (JSmol)
  • O=S(=O)(N)c3ccc(c2c(onc2c1ccccc1)C)cc3
  • InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) Yes check.svgY
  • Key:LNPDTQAFDNKSHK-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995. [2]

Contents

Valdecoxib was manufactured and marketed under the brand name Bextra by G. D. Searle & Company as an anti-inflammatory arthritis drug. [3] It was approved by the United States Food and Drug Administration (FDA) on November 20, 2001, to treat arthritis and menstrual cramps, [4] [5] and was available by prescription in tablet form until 2005 when the FDA requested that Pfizer withdraw Bextra from the American market. [6] The FDA cited "potential increased risk for serious cardiovascular (CV) adverse events," an "increased risk of serious skin reactions" and the "fact that Bextra has not been shown to offer any unique advantages over the other available NSAIDs." [6]

In 2009, Bextra was at the center of the "largest health-care fraud settlement and the largest criminal fine of any kind ever." [4] [7] Pfizer paid a $2.3 billion civil and criminal fine. Pharmacia & Upjohn, a Pfizer subsidiary, violated the United States Food, Drug and Cosmetic Act for misbranding Bextra "with the intent to defraud or mislead." [3]

A water-soluble and injectable prodrug of valdecoxib, parecoxib, is marketed in the European Union under the tradename Dynastat.

Uses until 2005

In the United States, the FDA approved valdecoxib for the treatment of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea. [8]

Valdecoxib was also used off-label for controlling acute pain and various types of surgical pain. [8]

Side effects and withdrawal from market

On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side effects were angina and Stevens–Johnson syndrome.

Pfizer first acknowledged cardiovascular risks associated with Bextra in October 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

In a large study published in The Journal of the American Medical Association in 2006, valdecoxib appeared less adverse for renal (kidney) disease and heart arrhythmia compared to Vioxx, but elevated renal risks were slightly suggested. [9]

2009 settlement for off-label uses promotions

On September 2, 2009, the United States Department of Justice fined Pfizer $2.3 billion after one of its subsidiaries, Pharmacia & Upjohn Company, pleaded guilty to marketing four drugs, including Bextra, "with the intent to defraud or mislead." [10] Pharmacia & Upjohn admitted to criminal conduct in the promotion of Bextra, and agreed to pay the largest criminal fine ever imposed in the United States for any matter, $1.195 billion. [11] A former Pfizer district sales manager was indicted and sentenced to home confinement for destroying documents regarding the illegal promotion of Bextra. [12] [13] In addition, a regional manager pleaded guilty to distribution of a misbranded product, and was fined $75,000 and 24 months on probation. [14]

The remaining $1 billion of the fine were paid to resolve allegations under the civil False Claims Act case and is the largest civil fraud settlement against a pharmaceutical company. Six whistleblowers were awarded more than $102 million for their role in the investigation. [15] Former Pfizer sales representative John Kopchinski acted as a qui tam relator and filed a complaint in 2004 outlining the illegal conduct in the marketing of Bextra. [16] Kopchinski was awarded $51.5 million for his role in the case because the improper marketing of Bextra was the largest piece of the settlement at $1.8 billion. [17]

Analytical methods

Several HPLC-UV methods [18] have been reported for valdecoxib estimation in biological samples like human urine. [19] [20] Valdecoxib has analytical methods for bioequivalence studies, [21] [22] metabolite determination, [23] [24] [19] estimation of formulation, [25] and an HPTLC method for simultaneous estimation in tablet dosage form. [26]

See also

Related Research Articles

<span class="mw-page-title-main">Nonsteroidal anti-inflammatory drug</span> Class of therapeutic drug for relieving pain and inflammation

Non-steroidal anti-inflammatory drugs (NSAID) are members of a therapeutic drug class which reduces pain, decreases inflammation, decreases fever, and prevents blood clots. Side effects depend on the specific drug, its dose and duration of use, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack, and kidney disease.

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849, in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Rofecoxib</span> Nonsteroidal anti-inflammatory drug

Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablets and as an oral suspension.

<span class="mw-page-title-main">Celecoxib</span> Nonsteroidal anti-inflammatory medication

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.

Cyclooxygenase-2 inhibitors, also known as coxibs, are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly target cyclooxygenase-2 (COX-2), an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

<span class="mw-page-title-main">Indometacin</span> Anti-inflammatory drug

Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.

In common law, a writ of qui tam is a writ through which private individuals who assist a prosecution can receive for themselves all or part of the damages or financial penalties recovered by the government as a result of the prosecution. Its name is an abbreviation of the Latin phrase qui tam pro domino rege quam pro se ipso in hac parte sequitur, meaning "[he] who sues in this matter for the king as well as for himself."

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Peter Rost (doctor)</span>

Peter Rost is an American former drug marketing executive who is most known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower. He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005. At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey. Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion. Rost settled with Wyeth for an undisclosed amount in 2003. At Pfizer, Rost filed a qui tam suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer. The U.S. Department of Justice declined to join in Rost's suit as the marketing violations had already been disclosed to the Department by Pfizer. Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities. Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant.

<span class="mw-page-title-main">Fenoprofen</span> NSAID analgesic and anti-inflammatory drug

Fenoprofen, sold under the brand name Nalfon among others, is a nonsteroidal anti-inflammatory drug (NSAID). Fenoprofen calcium is used for symptomatic relief for rheumatoid arthritis, osteoarthritis, and mild to moderate pain. It has also been used to treat postoperative pain. It is available as a generic medication.

The ethics involved within pharmaceutical sales is built from the organizational ethics, which is a matter of system compliance, accountability and culture. Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy. Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.

Naproxcinod (nitronaproxen) is a nonsteroidal anti-inflammatory drug (NSAID) developed by the French pharmaceutical company NicOx. It is a derivative of naproxen with a nitroxybutyl ester to allow it to also act as a nitric oxide (NO) donor. This second mechanism of action makes naproxcinod the first in a new class of drugs, the cyclooxygenase inhibiting nitric oxide donators (CINODs), that are hoped to produce similar analgesic efficacy to traditional NSAIDs, but with less gastrointestinal and cardiovascular side effects.

David Franklin is an American microbiologist and former fellow of Harvard Medical School who while employed by Parke-Davis filed the 1996 whistleblower lawsuit exposing their illegal promotion of Neurontin (gabapentin) for off-label uses. Franklin's suit, filed on behalf of the citizens of the United States under the qui tam provisions of US federal and state law, uncovered illegal pharmaceutical industry practices and created new legal precedent that resulted in a cascade of criminal convictions and civil and criminal penalties against Pfizer and several other pharmaceutical companies totalling more than $7 billion. Civil cases also followed Franklin v. Parke-Davis. Insurance companies, led by Kaiser Permanente, sued Pfizer for fraud and violation of the federal Racketeer Influenced and Corrupt Organizations Act; the Kaiser case settled in April 2014 after Pfizer's appeal at the US Supreme Court was rejected. Franklin v. Pfizer also spawned more than a thousand wrongful death (suicide) suits associated with use of Neurontin. Numerous books have addressed the social, economic and healthcare implications of Dr. Franklin's stance and actions. The settlement was the first off-label promotion settlement under the False Claims Act.

<span class="mw-page-title-main">Wyeth</span> American pharmaceutical company

Wyeth Pharmaceuticals Inc. was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.

<span class="mw-page-title-main">Stefan P. Kruszewski</span> American clinical and forensic psychiatrist

Stefan Philip Kruszewski is an American clinical and forensic psychiatrist, active as a whistleblower in medically related cases. He is principal in the company which bears his name, Stefan P. Kruszewski, M.D. & Associates, P.C. in Harrisburg, Pennsylvania.

Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.

Marketing of off-label use is advertising the use of drugs for purposes not approved by the regional government. The practice is often illegal and has led to most of the largest pharmaceutical settlements after Franklin v. Parke-Davis, in which a court ruled off-label marketing a violation of the False Claims Act.

References

  1. ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 52X. ISBN   9783527607495.
  3. 1 2 "Pfizer fined $2.3B in record fraud settlement Pharma giant illegally promoted product: Justice Department says, in largest health care fraud settlement in history". Washington: CNN. 2 September 2009. Retrieved 28 December 2015.
  4. 1 2 Gardiner H (2 September 2009). "Pfizer Pays $2.3 Billion to Settle Marketing Case". New York Times. Retrieved 28 December 2015.
  5. ↑ "Valdecoxib. U.S. FDA Drug Approval". Thomson Micromedex. Retrieved June 8, 2007.
  6. 1 2 "Information for Healthcare Professionals: Valdecoxib (marketed as Bextra)". U.S. Food and Drug Administration. 2005. Retrieved 28 December 2015.
  7. ↑ Elkind P, Reingold J (28 July 2011). "Inside Pfizer's palace coup". Fortune. Retrieved 28 December 2015.
  8. 1 2 "Pfizer to pay $2.3 billion to resolve criminal and civil health care liability relating to fraudulent marketing and the payment of kickbacks". Stop Medicare Fraud, US Dept of Health & Human Svc, and of Justice. Archived from the original on 2012-08-30. Retrieved 2012-07-04.
  9. ↑ Zhang J, Ding EL, Song Y (October 2006). "Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials". JAMA. 296 (13): 1619–1632. doi:10.1001/jama.296.13.jrv60015. PMID   16968832. Archived from the original on 2020-11-05. Retrieved 2006-09-17.
  10. ↑ "Pfizer agrees record fraud fine", BBC, 2009-09-02
  11. ↑ "Pharmacia & Upjohn Company Inc Pleads Guilty to Fraudulent Marketing of Bextra". The United States Attorney's Office, District of Massachusetts. 15 September 2009. Archived from the original on 7 December 2009. Retrieved 2009-10-16.
  12. ↑ "Ex-Pfizer Manager Found Guilty of Obstruction". The United States Department of Justice - United States Attorney's Office - District of Massachusetts. 17 March 2009. Archived from the original on 1 June 2009. Retrieved 16 October 2009.
  13. ↑ Edwards J (2009-06-26). "Pfizer's Off-Label Bextra Team Was Called "The Highlanders" - CBS News". Industry.bnet.com. Archived from the original on June 29, 2009. Retrieved 2019-06-06.
  14. ↑ "Pharmaceutical Company Manager Sentenced for Off-Label Marketing". The United States Department of Justice - United States Attorney's Office - District of Massachusetts. 18 June 2009. Archived from the original on 1 September 2009. Retrieved 16 October 2009.
  15. ↑ "Justice Department Announces Largest Health Care Fraud Settlement in Its History: Pfizer to Pay $2.3 Billion for Fraudulent Marketing". Federal Bureau of Investigation - Press Release. 2 September 2009. Archived from the original on 9 September 2010. Retrieved 28 July 2016.
  16. ↑ "Pfizer settlement and Bextra whistleblower case: News stories and court documents". Whistleblower News | Articles, Blogs, & Insights. Phillips & Cohen LLP. Archived from the original on 5 February 2011. Retrieved 6 June 2019.
  17. ↑ "Bextra whistleblower case leads to record-setting Pfizer settlement". Whistleblower news. Phillips & Cohen LLP. Archived from the original on 29 December 2010. Retrieved 2019-06-06.
  18. ↑ Sahu PK, Annapurna MM (2011). Analytical method development by liquid chromatography. Germany: LAP Lambert Academic Publisher. ISBN   978-3-8443-2869-1.
  19. 1 2 Zhang JY, Fast DM, Breau AP (February 2003). "Determination of valdecoxib and its metabolites in human urine by automated solid-phase extraction-liquid chromatography-tandem mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 785 (1): 123–134. doi:10.1016/s1570-0232(02)00863-2. PMID   12535845.
  20. ↑ Sane RT, Menon S, Deshpande AY, Jain A (February 2005). "HPLC determination and pharmacokinetic study of valdecoxib in human plasma". Chromatographia. 61 (3–4): 137–41. doi:10.1365/s10337-004-0442-2. S2CID   95275785.
  21. ↑ Sahu PK, Sankar KR, Annapurna MM (2011). "Determination of Valdecoxib in Human Plasma Using Reverse Phase HPLC" (PDF). Journal of Chemistry. 8 (2): 875–881. doi: 10.1155/2011/148938 .
  22. ↑ Mandal U, Jayakumar M, Ganesan M, Nandi S, Pal TK, Chakraborty MK, Roy Chowdhary A, Chattoraj TK (2004). "[title]". Indian Drugs. 41: 59.
  23. ↑ Zhang JY, Fast DM, Breau AP (September 2003). "Development and validation of an automated SPE-LC-MS/MS assay for valdecoxib and its hydroxylated metabolite in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 33 (1): 61–72. doi:10.1016/s0731-7085(03)00349-2. PMID   12946532.
  24. ↑ Werner U, Werner D, Hinz B, Lambrecht C, Brune K (March 2005). "A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma". Biomedical Chromatography. 19 (2): 113–118. doi:10.1002/bmc.423. PMID   15473012.
  25. ↑ Sutariya VB, Rajashree M, Sankalia MG, Priti P (2004). "Spectrophotometric Estimation Of Valdecoxib In Pure Form And Tablets". Indian Journal of Pharmaceutical Sciences. 66 (3): 360–362.
  26. ↑ Gandhimathi M, Ravi TK, Shukla N, Sowmiya G (January 2007). "High Performance Thin Layer Chromatographic Method for Simultaneous Estimation of Paracetamol and Valdecoxib in Tablet Dosage Form". Indian Journal of Pharmaceutical Sciences. 69 (1): 145. doi: 10.4103/0250-474X.32133 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.